Meanwhile, factors that can impair immunotherapy outcomes include a β2 microglobulin mutation in tumor cells [89], increased expression of other inhibitory checkpoints on terminally exhausted T-cells [90], and tumor cells’ resistance to IFN-γ [91]. The gene discussed is IFNG; the disease is neoplasm.